Completed PHASE2 INTERVENTIONAL 1-arm NCT00096083

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver

Sponsor: Delcath Systems Inc.

Conditions Cancer

Interventions isolated perfusion melphalan

Updated 6 times since 2017 Last updated: Oct 22, 2013 Started: Sep 30, 2004 Primary completion: Aug 31, 2012 Completion: Aug 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00096083, this PHASE2 trial focuses on Cancer and remains completed. Sponsored by Delcath Systems Inc., it has been updated 6 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Delcath Systems Inc.
National Cancer Institute (NCI)

Data source: Delcath Systems Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States